Corporate Member Update- BeiGene

Please review the update from BeiGene below to announce WAC pricing and that the Centers for Medicare and Medicaid Services (CMS) has assigned a permanent drug-specific J-code TEVIMBRA (tislelizumab-jsgr) injection, for intravenous use, effective October 1, 2024. The J-code (J9329) and WAC are detailed in the attached link below.

Click here for more information.